Clinical Evidence 4
Established safety and tolerability: IT’S ON™ Commonly observed adverse reactions (incidence ≥5% and at least twice the rate of placebo) were extrapyramidal disorder, application site reaction, and weight gain1 SECUADO® had a discontinuation rate similar to placebo1 A total of 4.9% of patients treated with SECUADO 3.8 mg/24 hours, 7.8% of patients treated with SECUADO […]
Clinical Evidence 3
Other clinical data Sublingual asenapine • The efficacy of SECUADO® was established, in part, on data from trials with the sublingual formulation of asenapine1 Maintenance of efficacy with sublingual asenapine1 Maintenance of efficacy has been demonstrated in a placebo-controlled, double-blind, multicenter, flexible dose with sublingual asenapine (5 mg or 10 mg twice daily based on […]
Clinical Evidence 2
Significant reduction in PANSS total score at week 6 (n=607)1 Both doses of SECUADO® were also statistically superior to placebo for Clinical Global Impressions – Severity (CGI-S)1 An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, and/or race1 The efficacy of SECUADO® was evaluated […]
Clinical Evidence
SECUADO® for the treatment of SCHIZOPHRENIA: IT’S ON™
